2705, boulevard Laurier
A-1602
Québec, Québec
Canada G1V 4G2
Dernières nouvelles
Information non disponible
- Ernst, MélanieEmployéCHUL+1 418-525-4444, poste 47044Melanie.Ernst@crchudequebec.ulaval.ca
2705, boulevard Laurier
A-1602
Québec, Québec
Canada G1V 4G2 - Giannakouros, PanagiotaEmployéCHUL+1 418-525-4444, poste 40192Panagiota.Giannak@crchudequebec.ulaval.ca
2705 Boulevard Laurier
A-0121
Québec, QC
Canada G1V 4G2
Selumetinib for symptomatic, inoperable plexiform neurofibromas in children with neurofibromatosis type 1: A national real-world case series
Article de revuePediatr Blood Cancer, 69 (8), 2022.
Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency
Article de revueNat Med, 28 (1), 2022.
Incidence of childhood cancer in Canada during the COVID-19 pandemic
Article de revueCMAJ, 193 (47), 2021.
Performance of the McGill Interactive Pediatric OncoGenetic Guidelines for Identifying Cancer Predisposition Syndromes
Article de revueJAMA Oncol, 7 (12), 2021.
DNA Polymerase and Mismatch Repair Exert Distinct Microsatellite Instability Signatures in Normal and Malignant Human Cells
Article de revueCancer Discov, 11 (5), 2021.
Screening for asymptomatic diabetes and metabolic comorbidities in pediatric patients during therapy for acute lymphoblastic leukemia
Article de revueJ Pediatr Endocrinol Metab, 34 (5), 2021.
Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance
Article de revueJ Clin Oncol, 39 (25), 2021.
Canadian Pediatric Neuro-Oncology Standards of Practice
Article de revueFront Oncol, 10 , 2020.
Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition
Article de revueJCO Precis Oncol, 4 , 2020.
Translating the Symptom Screening in Pediatrics Tool (SSPedi) into French and among French-speaking children receiving cancer treatments, evaluating understandability and cultural relevance in a multiple-phase descriptive study
Article de revueBMJ Open, 10 (4), 2020.
Projets terminés récemment
- Étude de phase II - Thérapie ciblée pour le gliome de bas grade réfractaire et le neurofibrome plexiforme, du 2018-04-01 au 2021-03-31
- Subvention pour la recherche clinique, du 2008-04-01 au 2021-03-31